Related Experiment Video

Updated: Aug 9, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1

Sharon Benzeno1, Goutham Narla, Jorge Allina

  • 1Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA.

Cancer Research
|June 3, 2004
PubMed

Insights

Kruppel-like factor 6 (KLF6), a tumor suppressor, inhibits cancer growth by interacting with cyclin D1. This interaction reduces retinoblastoma protein phosphorylation and promotes cell cycle arrest, suggesting KLF6

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Cycle Regulation

Background:

  • Kruppel-like factor 6 (KLF6) is recognized as a tumor suppressor gene frequently inactivated in various cancers, including prostate, colon, and astrocytic gliomas.
  • Understanding the molecular mechanisms by which KLF6 exerts its tumor-suppressive functions is crucial for developing targeted cancer therapies.

Purpose of the Study:

  • To elucidate the specific molecular interactions and pathways through which KLF6 mediates growth inhibition in cancer cells.
  • To investigate the role of KLF6 in regulating cell cycle progression and its interplay with key cell cycle regulatory proteins.

Main Methods:

  • Investigated the interaction between KLF6 and cyclin D1 using co-immunoprecipitation assays.
  • Assessed the effect of KLF6 on retinoblastoma protein (Rb) phosphorylation at Ser(795) via Western blotting.
  • Analyzed the impact of KLF6 on cyclin D1-cyclin-dependent kinase (cdk) 4 complexes and p21(Cip/Kip) redistribution to cdk2.

Main Results:

  • KLF6 directly interacts with cyclin D1, leading to decreased phosphorylation of the retinoblastoma protein (Rb) at Ser(795).
  • Introduction of KLF6 disrupts the formation of cyclin D1-cdk4 complexes.
  • KLF6 promotes the redistribution of p21(Cip/Kip) to cdk2, inducing a G(1) phase cell cycle arrest.

Conclusions:

  • KLF6 functions as a critical regulator of cell proliferation by inhibiting cyclin D1/cdk4 activity through convergence with the Rb pathway.
  • These findings highlight KLF6 as a key mediator of growth suppression and a potential therapeutic target in cancers where its activity is compromised.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...